



The Clinical TMS Society

Clinical Standards Committee Meeting Minutes
August 14, 2025 @ 2pm ET / 1pm CT / 12pm MT / 11am PT
August 15, 2025 @ 4am AEST
Via Zoom

"Members are reminded to disclose any changes in Conflict of Interest (COI) information since the most recent disclosure and follow all COI policies."

Clinical Standards Committee Roll Call | Attended ☒ | Did Not Attend ☐

Co-Chair	Joseph Taylor, MD, PhD	<input checked="" type="checkbox"/>	Co-Chair	Saydra Wilson, MD	<input checked="" type="checkbox"/>
Member	Scott Aaronson, MD	<input checked="" type="checkbox"/>	Member	Rebecca Allen, MD, MPH	<input checked="" type="checkbox"/>
Member/ VP	Tracy Barbour, MD	<input checked="" type="checkbox"/>	Member	Daniel Blumberger, MD	<input checked="" type="checkbox"/>
Member	Suneel Chamoli, MBBS, MD, FRANZCP	<input checked="" type="checkbox"/>	Member	Pilar Cristancho, MD	<input checked="" type="checkbox"/>
Member	Andrew Kozel, MD, MSCR, DFAPA, FCTMSS	<input checked="" type="checkbox"/>	Member	Dino Santoro, MD	<input checked="" type="checkbox"/>
Member	Subha Subramanian, MD	<input checked="" type="checkbox"/>	Member	Rick Trautner, MD, FCTMSS	<input checked="" type="checkbox"/>
Non-Voting Member	Linday Oberman, MD	<input checked="" type="checkbox"/>			
President	Joshua Brown, MD, PhD	<input checked="" type="checkbox"/>			

Guests & Staff: None

I. Dr. Taylor called the meeting to order at 2:01 pm (ET)

II. Review May and July meeting minutes

The Committee reviewed the minutes.

There was a motion to approve the May 8 and July 10, 2025 meeting minutes, Seconded, Approved.

III. Unfinished Business

A. Supportive statement on the evidence for TMS compared to other augmentation or switch strategies in treatment-resistant depression

- The statement was approved by the Executive Committee. It is posted on the Clinical Standards member resource page. The Committee will determine if it should also be made public and/or published in the journal.
- A concern was raised that publishing statements in the journal could imply they are peer-reviewed when they are not. The Committee agreed to recommend statement publication to the Editorial Board, which will determine whether they should be published.

ACTION- Dr. Wilson and Dr. Barbour will meet to develop a proposal outlining the publication of the supportive statement before the next meeting.

B. Device Clearance Table Review

- The table focuses on FDA clearance with the potential to expand with international data if contributors from other regions participate.
- A task force was formed and includes Dr. Kozel, Dr. Cristancho, Dr. Chamoli, and Dr. Subramanian.

ACTION- The task force will meet to develop a recommendation for how often the table should be updated and decide on its access and placement on the website before the next meeting.

IV. New Business

A. Outdated statements on the website

- Concern was raised about outdated statements on the website causing confusion.
- There was a suggestion to archive or remove outdated statements from the public site.
- Policy reminder – Internal statements should be reviewed every three years and external statements reviewed annually.

ACTION- Dr. Taylor will contact PMG and ask them to locate all past statements. The Committee will review the statements, decide to archive as needed, and discuss optimal website organization at the next meeting.

B. Possible statement about EXOMIND marketing their TMS treatments for cognitive enhancement and stress reduction in healthy adults

- A concern about EXOMIND's marketing for cognitive enhancement and stress reduction in healthy adults using a six session protocol was brought to the Committee.
- The Committee identified key issues:
 - Marketing may give misleading impression of efficacy.
 - Protocol not backed by scientific evidence, though the technology itself is evidence based.
 - Wellness marketing may circumvent clinical advertising restrictions.

- There was a suggestion to develop a general statement on evidence based TMS use and advertising ethics to address recurring issues and maintain a living list of protocols/indications of concern without naming companies.
- It was suggested to add a section to the website with a brief overview of treatments and evidence levels, along with a list of treatments that are FDA-cleared, supported by strong evidence, and those with no evidence.

There was a motion to create a clear, general, concise, outward-facing statement that explains how to consider level of evidence, and what is considered to be good and appropriate advertising and then create an ongoing list of either specific protocols that are not evidence-based or harmful and/or specific indications that are not evidence-based, with a quick process for adding new areas of concern to the list, Seconded, Approved.

- The Committee would like to continue to discuss the details of how to manage this statement and list on the website at the next meeting.

ACTION- Dr. Allen and Dr. Wilson volunteered to draft the statement.

V. Committee Projects and Informational Items

A. Recommendations for ratings scales (Partnering with Research Committee)

No report.

B. Create guidelines for repeat MT's

No report.

C. Review of literature on treatment extension

No report.

D. Follow up on TMS pregnancy registry and consider a statement

No report.

E. Evaluate TMS evidence for bipolar depression and consider a statement

- After conversations with Brainsway and Neuronetics, it was reported that registries have very limited bipolar disorder data and what is there has questionable validity because of the challenges with insurance companies.

F. Evaluate TMS evidence after ECT non-response and consider a statement

No report.

G. Revisit statement policies and processes

No report.

VI. Adjourn Meeting at 3:00pm (ET)

VII. Next Meeting: Thursday, September 11, 2025 @ 2pm ET / 1pm CT / 12pm MT / 11am PT / and Friday, September 12, 2025 @ 4am AEST

2025-2026 Committee Goals:

- Create guidelines for repeat MT's. *In progress*
 - Consider treatment extension review of literature. *In progress*
 - Develop a procedure for rapid communication between Clinical Standards and Insurance Committees. *In progress*
 - Follow up on the TMS pregnancy registry and consider a statement. *In progress*
 - Evaluate TMS evidence for bipolar depression and consider a statement. *In progress*
 - Evaluate TMS evidence after ECT non-response and consider a statement. *In progress*
 - Revisit statement policies and processes. *In progress*
-